FDA Rejects Keytruda Dosing, Fast Tracks Tecentriq Lung Cancer Review
Contrasts With EMA Decision
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first